Advertisement
Advertisement

LPCN

LPCN logo

Lipocine Inc.

2.37
USD
Sponsored
-0.02
-0.84%
May 08, 15:58 UTC -4
Closed
exchange

After-Market

2.38

+0.01
+0.63%

Lipocine Inc. Profile

About

Lipocine, Inc. is a specialty pharmaceutical company. It develops pharmaceutical products for use in men's and women's health. The Company's lead product candidate, LPCN 1021, is in Phase 3 and is targeted to treat symptoms of low testosterone for men in need of testosterone replacement therapy. Its additional pipeline candidates include LPCN 1111, a next generation oral testosterone therapy product, and LPCN 1107, indicated for the prevention of preterm birth and is currently in Phase 1. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Info & Links

CEO

Mahesh V. Patel

Headquarters

675 ARAPEEN DRIVE, SUITE 202
SALT LAKE CITY, UT 84108, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.lipocine.com

Auditor

Tanner LLP

Share holders

86

Employees

14

Lipocine Inc. Statistics

Valuation Measures

Market Capitalization2

19.14M

Enterprise Value

14.12M

Enterprise Value/EBITDA(ttm)

-1.15

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

7.72

Price to Book(mrq)

0.80

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-487.00%

Profit Margin(ttm)

-1332.33%

Return on Equity(ttm)

-59.30%

Return on Invested Capital(ttm)

-61.49%

Return on Assets(ttm)

-53.37%

Income Statement

Revenue(ttm)

2.00M

Revenue Per Share(ttm)

0.24

Gross Profit(ttm)

2.00M

EBITDA(ttm)3

-12.30M

Net Income Available to Common(ttm)

-11.43M

Diluted EPS(ttm)

-1.69

Share Statistics

Beta (5Y Monthly)

1.09

52-Week Change

-26.69%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

8.24M

Dividend Yield

0.00%

Float4

6.84M

% Held by Insiders

6.35%

% Held by Institutions

9.11%

Balance Sheet

Total Cash(mrq)

24.73M

Total Cash Per Share(mrq)

3.00

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

6.68%

Quick Ratio(mrq)

6.68%

Book Value Per Share(mrq)

2.35

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.71

Free Cash Flow(ytd)

-9.76M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement